PLEASANTON, Calif., Feb. 5, 2025 -- Medea Inc., a medical products and pharmaceutical distribution company, fulfilled a contract award by the State of California to supply it with 19.7 million N95 respirators for the State's emergency stockpile. Medea was able to fulfill the contract months ahead of schedule. The contract is part of a five-year Leveraged Procured Agreement (LPA) between the California Department of General Services (DGS) and Medea, which was one of over a hundred suppliers selected by DGS. Any federal, state or local agency may procure N95s in bulk through Medea's LPA.
In 2020, Medea supplied crucial PPE, including more than 26 million N95 respirators and face masks to the Federal Emergency Management Agency (FEMA). Additionally, in 2022, the Department of Defense awarded Medea a $190 million contract for rapid antigen tests.
"We have deep roots in California and stand ready in support of current and future emergency preparedness for our state and local communities," said Brandon Laidlaw, CEO of Medea Inc. "Medea is proud to have delivered all 19.7 million N95 respirators months ahead of schedule."
Medea is a trusted partner of federal, state and local agencies as a distributor of FDA-approved medical products and opioid antagonist drugs.
To learn more, visit medeausa.com.
About Medea Inc.
Medea Inc., established in 2014 and headquartered in the Silicon Valley Economic Region and Orange County, California, specializes in the distribution of naloxone and other FDA-approved medical products to all levels of government, healthcare and retail channels. Medea also offers expeditious eCommerce product fulfillment services. For more information regarding Medea and its opioid reversal drugs, please visit medeausa.com.
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
